Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Antiviral Molnupiravir Associated with Reduced Risk of Hospitalisation or Death in COVID-19 Patients

28 Feb 2022

Chloe FUNG

Share

This content is sponsored. It is intended for healthcare professionals only.

// INFECTIOUS DISEASE Medical writer: | Last updated: | In: Article Keywords Serious coronavirus disease 2019 (COVID-19) symptoms in a widespread outbreak may impose risks on patients’ lives and overwhelm the healthcare system. A new oral antiviral, molnupiravir, was evaluated for its ability

Antiviral Molnupiravir Associated with Reduced Risk of Hospitalisation or Death in COVID-19 Patients

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026